Evidence map›Paper›PMID 30863033›Full record

ReviewClinical interventions in aging2019

Current and emerging biomarkers of frailty in the elderly.

Ahmed Al Saedi, Jack Feehan, Steven Phu, Gustavo Duque

Abstract readReview
In one paragraph

Review in Clinical interventions in aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. High frailty index scores predict mortality and changes in blood-based biomarkers in aging female mice.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. The Association Between Urbanization and Frailty Status in China.Journal of applied gerontology : the official journal of the Southern Gerontological Society · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ahmed Al SaediAustralian Institute for Musculoskeletal Science (AIMSS), University of Melbourne and Western Health, St Albans, Melbourne, VIC, Australia, gustavo.duque@unimelb.edu.au.
Jack FeehanAustralian Institute for Musculoskeletal Science (AIMSS), University of Melbourne and Western Health, St Albans, Melbourne, VIC, Australia, gustavo.duque@unimelb.edu.au.
Steven PhuAustralian Institute for Musculoskeletal Science (AIMSS), University of Melbourne and Western Health, St Albans, Melbourne, VIC, Australia, gustavo.duque@unimelb.edu.au.
Gustavo DuqueAustralian Institute for Musculoskeletal Science (AIMSS), University of Melbourne and Western Health, St Albans, Melbourne, VIC, Australia, gustavo.duque@unimelb.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The term "frailty" is used to describe a subset of older adults who appear weaker and more vulnerable than their age-matched counterparts, despite having similar comorbidities, demography, sex, and age. The diagnosis of frailty is usually clinical and based on specific criteria, which are sometimes inconsistent. Therefore, there is an increasing need to identify and validate robust biomarkers for this condition. In this review, we summarize current evidence on the validity and practicality of the most commonly used biomarkers for frailty, while also comparing them with new upcoming strategies to identify this condition.

Indexed as

Mesenchymal Stem CellsAgedAged, 80 and overBiomarkersC-Reactive ProteinFrailtyGlycated HemoglobinHormonesHumansInflammationInterleukin-6Lamin Type ATumor Necrosis Factor-alphaBiomarkersC-Reactive ProteinGlycated HemoglobinHormonesInterleukin-6Lamin Type ATumor Necrosis Factor-alphabiomarkersCOP cellsdisabilityelderlyfrailtymesenchymal stem cells

Identifiers

PMID30863033
PMCPMC6388773

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.